Personalized immunoglobulin aptamers for detection of multiple myeloma minimal residual disease in serum

Publication year: 2020
Authors: Claudia Tapia-Alveal, Timothy R. Olsen, Tilla S. Worgall

Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY, 10032, USA

Published in: Communications Biology, Vol. 3 (2020), 781
doi: 10.1038/s42003-020-01515-x

Multiple myeloma (MM) is a neoplasm of plasma cells that secrete patient specific monoclonal immunoglobulins. A recognized problem in MM treatment is the early recognition of minimal residual disease (MRD), the major cause of relapse. Current MRD detection methods (multiparameter flow cytometry and next generation sequencing) are based on the analysis of bone marrow plasma cells. Both methods cannot detect extramedullary disease and are unsuitable for serial measurements. We describe the methodology to generate high affinity DNA aptamers that are specific to a patient’s monoclonal Fab region. Such aptamers are 2000-fold more sensitive than immunofixation electrophoresis and enabled detection and quantification of MRD in serum when conventional MRD methods assessed complete remission. The aptamer isolation process that requires small volumes of serum is automatable, and Fab specific aptamers are adaptable to multiple diagnostic formats including point-of-care devices.

MP-SPR keywords: antibody-aptamer interaction, binding, regenerable avidin